India Simplifies Rules to Spur Drug Development
Indian experts argue that simplifying regulations and adopting AI, non-animal preclinical methods, and innovative clinical trial designs could lower drug development costs and stimulate new-molecule research, especially for rare diseases. The article cites CDSCO oversight under NDCT-2019, projected Indian pharma revenue of about $130 billion by 2030, and high R&D costs ($100 million–$1 billion) as barriers; it urges policy changes including Rule 101 orphan-drug provisions.
Key Points
- 1Report projects India pharma revenue reaching $130 billion by 2030, driven mainly by generics.
- 2Noting R&D costs of $100 million–$1 billion deter new-molecule development, especially for rare diseases.
- 3Recommend regulatory simplification, AI, non-animal models, and adaptive trials to reduce costs and incentivize innovation.
Scoring Rationale
Policy-oriented and practical recommendations with credible authorship, but limited novelty and lacking formal government or empirical evidence.
Sources
Public references used for this report.
Practice with real Ad Tech data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Ad Tech problems
